Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Fineline Cube Sep 10, 2026
Company Deals PIC

CellStore Signs Strategic Partnership Memorandum With Shanghai Cell Therapy Group – Deepening Cooperation in Cell Cryopreservation, Product Application Validation, and Industrial Synergy Across Cell and Gene Therapy

Fineline Cube Sep 10, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Deals

Lee’s Pharmaceutical Secures Exclusive Greater China License for OC‑3 – Next‑Generation PARP1‑Selective Inhibitor from US Biotech 1cBio Targeting BRCA‑Mutant Cancers

Fineline Cube Sep 10, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company

Sino Biopharmaceutical Reports Record H1 Revenues of RMB 15.87 Billion, Net Profit Soars 139.7%

Fineline Cube Aug 14, 2024

Sino Biopharmaceutical Ltd (HKG: 1177) reported robust financial results for the first half of 2024,...

Company Drug

Wantai Biological’s HPV Vaccine Receives Priority Review from China’s CDE

Fineline Cube Aug 14, 2024

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) has announced that its nine-valent recombinant...

Company Drug

Hengrui Pharmaceuticals Launches Phase II Trial for SHR7280 to Treat Uterine Fibroids

Fineline Cube Aug 14, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, has received approval...

Company Legal / IP R&D

HuidaGene Secures Patent for Innovative CRISPR-Cas12i System in China

Fineline Cube Aug 14, 2024

HuidaGene (Shanghai) Biotechnology Co., Ltd, a China-based biotech firm, has secured patent approval from the...

Company Drug

GSK Initiates Phase III Study for RSV Vaccine in China Following U.S. Approval

Fineline Cube Aug 14, 2024

GSK (NYSE: GSK), the UK-based pharmaceutical giant, has registered a Phase III bridging study for...

Company Drug

Sihuan Pharmaceutical Secures NMPA Approval for First Biosimilars of Novo Nordisk’s Diabetes Drugs

Fineline Cube Aug 14, 2024

Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has secured separate marketing approvals from China’s National...

Company

Gilead Buys Out Janssen’s Royalty Rights to Seladelpar for Primary Biliary Cholangitis Treatment

Fineline Cube Aug 13, 2024

Gilead (NASDAQ: GILD)’s financial report for the second quarter of 2024, followed by an earnings...

Company

Legend Biotech CEO Addresses Biosecure Act Concerns Amid Q2 2024 Earnings Report

Fineline Cube Aug 13, 2024

Legend Biotech Corporation (Nasdaq: LEGN), a leading Chinese biopharmaceutical company, has released its financial results...

Company Deals

Ocumension Therapeutics Partners with Alcon Laboratories, Secures Rights to Ophthalmic Products in China

Fineline Cube Aug 13, 2024

Ocumension Therapeutics (HKG: 1477), a biopharmaceutical company based in China, has entered into a strategic...

Company Drug

Pfizer’s Hemophilia Treatment Marstacimab Accepted for Review in China

Fineline Cube Aug 13, 2024

The China Center for Drug Evaluation (CDE) has accepted for review a market approval filing...

Company Drug

Junshi Biosciences Submits Twelfth Indication for PD-1 Inhibitor Loqtorzi in China

Fineline Cube Aug 13, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced a new indication filing...

Company Drug

Nanjing Sanhome’s Oritinib Ships Widely for EGFR-mutated NSCLC Treatment in China

Fineline Cube Aug 13, 2024

Nanjing Sanhome Pharmaceutical Co., Ltd, a notable player in the pharmaceutical sector, has announced the...

Company Drug

Boehringer Ingelheim’s Zongertinib Earns Breakthrough Designation in China for HER2-Mutated NSCLC

Fineline Cube Aug 13, 2024

Boehringer Ingelheim, a leading German pharmaceutical company, has received a significant endorsement from China’s Center...

Legal / IP Policy / Regulatory

China’s SAMR Proposes Antitrust Guidelines to Regulate Pharmaceutical Industry

Fineline Cube Aug 13, 2024

The State Administration for Market Regulation (SAMR) in China has unveiled a draft proposal for...

Company Drug

IASO Biotherapeutics’ CAR-T Therapy Fucaso Gets FDA Green Light for Lupus Treatment

Fineline Cube Aug 13, 2024

IASO Biotherapeutics, a Chinese biotech firm, has received Investigational New Drug (IND) approval from the...

Company Drug

Ascendis Pharma’s Hypoparathyroidism Therapy Yorvipath Wins FDA Nod, Fills Market Gap

Fineline Cube Aug 13, 2024

This week, the U.S. Food and Drug Administration (FDA) granted market approval to Ascendis Pharma...

Company Deals

Siemens Healthineers Partners with Cedars-Sinai to Boost Medical Cooperation and Education

Fineline Cube Aug 13, 2024

Siemens Healthineers AG, a global leader in medical technology, has announced a strategic partnership with...

Company Medical Device

Artech Medical’s Balloon Cryoablation Catheter Wins NMPA Nod for Atrial Fibrillation Treatment

Fineline Cube Aug 13, 2024

Shanghai Artech Medical Technology Co., Ltd., a company known for its innovation in the medical...

Hospital

Former Hainan Medical University President Li Jingquan Expelled for Serious Disciplinary Violations

Fineline Cube Aug 13, 2024

Hainan’s disciplinary inspection committee has announced the expulsion of Li Jingquan, the former president of...

Company Drug

Pfizer’s RSV Vaccine Abrysvo Shows Strong Protection in Immunocompromised Adults, Phase III Sub-Study Reveals

Fineline Cube Aug 13, 2024

Pfizer Inc. (NYSE: PFE), a pharmaceutical titan based in the US, has announced encouraging topline...

Posts pagination

1 … 367 368 369 … 718

Recent updates

  • Lee’s Pharmaceutical Secures Exclusive Greater China License for OC‑3 – Next‑Generation PARP1‑Selective Inhibitor from US Biotech 1cBio Targeting BRCA‑Mutant Cancers
  • METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform
  • Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection
  • CSPC Wins NMPA Clinical Trial Approvals for Two Long‑Acting Injections – Weekly Rotigotine (SYH9087) for Parkinson’s Disease and World’s First Ready‑to‑Use Monthly Goserelin (SYH9102) for Solid Tumours
  • HBM Partner Solstice Oncology Launches with US$225 Million Series A Led by RA Capital – Advancing Second‑Generation CTLA‑4 Antibody Porustobart in Neoadjuvant Oncology
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Lee’s Pharmaceutical Secures Exclusive Greater China License for OC‑3 – Next‑Generation PARP1‑Selective Inhibitor from US Biotech 1cBio Targeting BRCA‑Mutant Cancers

Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Company Drug

CSPC Wins NMPA Clinical Trial Approvals for Two Long‑Acting Injections – Weekly Rotigotine (SYH9087) for Parkinson’s Disease and World’s First Ready‑to‑Use Monthly Goserelin (SYH9102) for Solid Tumours

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.